[{"address1": "3400 One First Canadian Place", "city": "Toronto", "state": "ON", "zip": "M5X 1A4", "country": "Canada", "website": "https://vaxil-bio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Gadi  Levin B.Com., C.A., CPA, M.B.A.", "age": 51, "title": "CEO & Chairman", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 37910, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA", "age": 72, "title": "Chief Financial Officer", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 9299, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riva  Kovjazin M.D.", "title": "Senior Scientist & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0, "open": 0.003, "dayLow": 0.003, "dayHigh": 0.003, "regularMarketPreviousClose": 0.0, "regularMarketOpen": 0.003, "regularMarketDayLow": 0.003, "regularMarketDayHigh": 0.003, "payoutRatio": 0.0, "volume": 10000, "regularMarketVolume": 10000, "averageVolume": 456, "averageVolume10days": 92, "averageDailyVolume10Day": 92, "bid": 0.0014, "ask": 0.009, "bidSize": 0, "askSize": 0, "marketCap": 16437481, "fiftyTwoWeekLow": 0.003, "fiftyTwoWeekHigh": 1.75, "fiftyDayAverage": 0.2891, "twoHundredDayAverage": 0.372275, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": "NaN", "currency": "USD", "tradeable": false, "enterpriseValue": 264290, "profitMargins": 0.0, "sharesOutstanding": 136979008, "heldPercentInsiders": 0.08165, "heldPercentInstitutions": 0.00014999999, "impliedSharesOutstanding": 834454016, "bookValue": 0.261, "priceToBook": 0.45977008, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -178000, "trailingEps": -0.04, "lastSplitFactor": "1:50", "lastSplitDate": 1747267200, "52WeekChange": -0.7, "SandP52WeekChange": 0.12632763, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "VXLLF", "underlyingSymbol": "VXLLF", "shortName": "VAXIL BIO LTD (CA)", "longName": "Vaxil Bio Ltd.", "firstTradeDateEpochUtc": 1459344600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9e7b383f-26e7-3815-92b9-aa2ae181b474", "messageBoardId": "finmb_108333814", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.12, "recommendationKey": "none", "totalCash": 448000, "totalCashPerShare": 0.164, "totalDebt": 0, "quickRatio": 27.471, "currentRatio": 43.118, "returnOnAssets": -0.14336, "returnOnEquity": -0.22153, "freeCashflow": -432500, "operatingCashflow": -240000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "CAD", "trailingPegRatio": null, "__fetch_time": "2025-07-01"}]